Navigation Links
Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
Date:3/3/2010

GSK's ASCIs represent a novel class of medicines designed to train the immune system to recognize and eliminate cancer cells in a highly specific manner.  These candidate cancer immunotherapeutics combine tumor antigens, delivered as purified recombinant proteins, and GSK's proprietary immunostimulants, which are specific combinations of immunostimulating compounds selected to increase the anti-tumor immune response.  ASCIs are being investigated in the clinic to support their use to reduce the risk of tumor recurrence following surgery, or to impact tumor growth in an early metastatic setting.  

The highly specific mode of action of GSK's ASCIs is linked to the development of diagnostic tools to aid in selecting patients eligible for the treatment, depending on the expression of the tumor antigens.  MAGE-A3 is a tumor-specific antigen that is expressed in a large variety of cancers, including melanoma, non-small cell lung cancer, liver and bladder cancer, with no expression in normal cells.  MAGE-A3 ASCI is an investigational compound and it is not approved for use in any indication in any country at this time.

Websites have been created to provide information on the ASCI approach and the DERMA clinical study. Please visit '/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... OAKS, Calif., April 21, 2015 Amgen (NASDAQ: ... first quarter of 2015. Key results include: , ... of 2014 to $5,033 million, with 12 percent product ... Prolia ® (denosumab), EPOGEN ® (epoetin alfa), ... Unfavorable changes in foreign exchange rates impacted total revenue ...
(Date:4/21/2015)... , 21. April 2015  CorTechs Labs, ... quantitative Analyse des Hirnvolumens freut sich, eine ... Pharmaunternehmen, bekannt geben zu können. Die Unternehmen ... des Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung ... Patienten mit multipler Sklerose als Ziel hat. ...
(Date:4/21/2015)... -- Lincoln Computer Services has taken a proactive approach to ... LCS donated 10 laptops and carts to the Good ... Home at Riverdale by RiverSpring ... is a creative, non-pharmacological approach to Alzheimer,s care that ... in the morning, start their day off in a ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2Lincoln Continues Support of the Community: Donates 10 Laptops for Alzheimer's Program 2
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will present updated results from its,Phase 2 ... a,poster discussion session at the International Association for ... on Lung Cancer in Seoul, Korea.,Details follow: ...
... - Positive Phase 2 Clinical Trial Results from PI-88 in ... $92.4 million in Raised Capital Highlight the Year ... PGL; Nasdaq: PGLA) today released its,financial results for the fiscal ... * Announced positive results from a Phase 2, 172 ...
Cached Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 2Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 3
(Date:4/21/2015)... April 21, 2015 Displays & Exhibits, ... in the trade show exhibit building industry, announced a ... sales offices of Absolute Exhibits in Tustin, California.“It is ... shoppers to observe the variation in quality as offered ... Exhibits,” explained Zenos Adduru. Mr. Adduru is the new ...
(Date:4/21/2015)... San Francisco, CA and Orlando, FL (PRWEB) April ... for Behavioral Health (National Council) will honor Dina ... Support Services for PREP (Prevention and Recovery in ... the National Council Award of Excellence: Peer Specialist ... NatCon15 awards ceremony, known as the Oscars of ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in ... to automatically send continuation of care documents (CCDs). ... improve communication with clinics and other ambulatory practices, they ... solution. , “Provider Alert will enable the physician ... they need to provide continuing care in real time,” ...
(Date:4/21/2015)... April 21, 2015 Grafika is pleased ... printer, Offset Impressions. , “We’re excited about ... of printing capabilities and knowledgeable team members,” according to ... allows us to offer an ever wider breadth of ... packaging, and specialty services we already offer. It ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 3Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 4Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... losing in a way that's making other communities in the ... a town of 80,000 outside Boston, have been taking part ... eating habits that stay with them throughout their lives. As ... those in nearby towns, and as they learn to eat ...
... felt on the world fashion map, it is attracting ... the ramp here but also try their luck in ... matured as designers stopped copying Western motifs blindly. India ... as becoming a profitable business destination for international buyers. ...
... functions may be vulnerable to Alzheimers disease if they ... blood vessels in the brain, says a study ... in the Journal of Neuroimaging, also suggests that people ... the disease than their peers. ,Alzheimers ...
... Elevated CO2 is considered to be a serious catalyst ... the ecosystem , including the insect-plant food chain link.Safeguarding ... and national economies. ,In research to be presented ... Plant Biologists in Chicago (July 7-11, 2007), scientists will ...
... who received the world's first face transplant 18 months ago said ... herself in the mirror with a combination of sadness and wonder. ... who have a face, a smile, facial expressions which allow them ... in an interview published in Saturday's edition of Le Monde. ...
... Africa on Friday after they came into contact with an ... ,Inspector Juanita Kilian said police had received a complaint ... of Johannesburg, about a "suspicious" envelope, she told public radio. ... this stage we cannot confirm that the contents were anthrax," ...
Cached Medicine News:Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 2Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 3Health News:Indian Fashion Beckons International Models 2Health News:Elevated Carbondioxide may Have Negative Impact on Ecosystem 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Digisonics has set the standard in ... review station, the only fully integrated ... multi-modality reporting., ,DigiView cardiology solutions bring ... professional reporting choices, an integrated clinical ...
... The menu-driven Vapro osmometer determines osmolality ... natural equilibrium. ,What you don't get are ... particles, or other conditions that interfere with ... percent in the clinical range) Vapro osmometer ...
Medicine Products: